Burlingame, CA, United States of America

Michael Siu

USPTO Granted Patents = 25 (Patent Applications = 22)

EPO Patents = 11 (Patent Applications = 17)

Average Co-Inventor Count = 8.8

ph-index = 4

Forward Citations = 47(Granted Patents)

Location History:

South San Francisco, CA (US) (2011 - 2018)
Burlingame, CA (US) (2013 - 2021)
San Francisco, CA (US) (2019 - 2023)

Company Filing History:

Hoffmann-la Roche Inc.

patents

2 out of 168

F. Hoffmann-la Roche Ag

patents

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12473301 - Isoquinoline compounds for the treatment of cancer (2025-11-18),

2. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),

3. 12338256 - Aza-tetracyclic oxazepine compounds and uses thereof (2025-06-24),

4. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),

5. 11612606 - 8-aminoisoquinoline compounds and uses thereof (2023-03-28),

6. 11129832 - Biheteroaryl compounds and uses thereof (2021-09-28),

7. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),

8. RE47848 - Biheteroaryl compounds and uses thereof (2020-02-10),

9. 10407424 - Naphthyridines as inhibitors of HPK1 (2019-09-10),

10. 10131675 - Tricyclic DLK inhibitors and uses thereof (2018-11-20),

11. 10028954 - Biheteroaryl compounds and uses thereof (2018-07-24),

12. 10028942 - 3-substituted pyrazoles and uses thereof (2018-07-24),

13. 10010549 - Biheteroaryl compounds and uses thereof (2018-07-03),

14. 9550777 - 3-substituted pyrazoles and use as DLK inhibitors (2017-01-24),

15. 9434732 - Triazolopyridine JAK inhibitor compounds and methods (2016-09-06),

Title: Michael Siu: Innovating in Pharmaceutical Chemistry

Introduction

Michael Siu is a prominent inventor based in Burlingame, California, known for his significant contributions to pharmaceutical chemistry. With a remarkable portfolio of 21 patents, he has made strides in developing innovative compounds for treating various diseases.

Latest Patents

Among his latest patents are his work on 8-aminoisoquinoline compounds and their applications. These compounds serve as inhibitors of HPK1 (hematopoietic kinase 1) and are essential in treating HPK1-dependent disorders, while also enhancing immune responses. His research includes methods for inhibiting HPK1, treating related disorders, enhancing immune function, and preparing carbonylamino-8-aminoisoquinoline compounds. Additionally, he has developed biheteroaryl compounds aimed at addressing neurodegenerative diseases, expanding the potential therapeutic approaches for patients.

Career Highlights

Michael Siu has built an impressive career in the pharmaceutical field, working with leading companies such as Genentech, Inc. and F. Hoffmann-La Roche AG. His collaborations and innovations within these organizations have contributed to advancements in drug discovery and development.

Collaborations

During his time in the industry, Michael has worked alongside talented professionals, including Snahel Patel and Alan G. Olivero. These collaborations have fostered a creative environment for innovation, paving the way for breakthrough developments in medicine.

Conclusion

Michael Siu's impressive record of patents and collaborations signifies his dedication to improving healthcare through innovative science. His research not only opens new pathways for treatment but also enhances our understanding of the underlying mechanisms of various diseases.

This text is generated by artificial intelligence and may not be accurate.